Cover Image

Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) i...

Full description

Saved in:
Bibliographic Details
Main Authors: Blank, Antje (Author) , Fürle, Kristin (Author) , Jäschke, Anja (Author) , Mikus, Gerd (Author) , Lehmann, Monika (Author) , Hüsing, Johannes (Author) , Heiss, Kirsten (Author) , Giese, Thomas (Author) , Carter, Darrick (Author) , Böhnlein, Ernst (Author) , Lanzer, Michael (Author) , Haefeli, Walter E. (Author) , Bujard, Hermann (Author)
Format: Article (Journal)
Language:English
Published: 31 January 2020
In: npj vaccines
Year: 2020, Volume: 5, Pages: 1-15
ISSN:2059-0105
DOI:10.1038/s41541-020-0160-2
Online Access:Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.1038/s41541-020-0160-2
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/s41541-020-0160-2
Get full text
Author Notes:Antje Blank, Kristin Fürle, Anja Jäschke, Gerd Mikus, Monika Lehmann, Johannes Hüsing, Kirsten Heiss, Thomas Giese, Darrick Carter, Ernst Böhnlein, Michael Lanzer, Walter E. Haefeli and Hermann Bujard
Description
Summary:A vaccine remains a priority in the global fight against malaria. Here, we report on a single-center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase 1a safety and immunogenicity clinical trial of full-length Plasmodium falciparum merozoite surface protein 1 (MSP1) in combination with GLA-SE adjuvant.
Item Description:Gesehen am 03.04.2020
Physical Description:Online Resource
ISSN:2059-0105
DOI:10.1038/s41541-020-0160-2

Similar Items